Sepsis News and Research

Latest Sepsis News and Research

1 in 4 Americans lacks timely access to optimal care during time-sensitive medical emergencies

Although most Americans live close to some type of emergency room, as many as one in four Americans are more than an hour away from the type of hospital that's most prepared to save their life during a time-sensitive medical emergency, according to a new University of Pennsylvania School of Medicine study published in the journal Annals of Emergency Medicine.

17 Mar 2009

Childhood diarrhoea needs greater research focus

The list of priority research questions focus on how to make the best use of interventions that are available today, in order to make the most difference, and ultimately save as many children's lives as possible.

11 Mar 2009

Researchers probe mechanisms of infection

A newly discovered receptor in a strain of Escherichia coli might help explain why people often get sicker when they're stressed.

10 Mar 2009

Wyeth's Prevenar vaccine for pneumococcal disease registered in Russia

Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year.

2 Mar 2009

Implicit licenses clinical stage antibody program from Lilly

Implicit Bioscience Ltd has announced the acquisition of the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.

25 Feb 2009

Researchers block immune cell rush behind deadly sepsis

Researchers have found a way to block the ability of white blood cells to sprint toward the sites of infection when such speed worsens the damage done by sepsis, the often fatal, whole-body bacterial infection, according to a study published today in the journal Blood.

24 Feb 2009

FDA issues early communication about Xigris safety

The U.S. Food and Drug Administration has announced that it is working with the maker of Xigris (drotrecogin alfa activated), Eli Lilly and Company, to further evaluate the incidence of serious bleeding events and death in patients who receive Xigris, a drug used to treat severe sepsis (a blood stream infection).

5 Feb 2009

Blocking off splenic artery helps liver transplant patients with small-for-size syndrome

Blocking off the splenic artery, either through surgical ligation or radiological coiling, helped six out of seven patients suffering from small-for-size syndrome after a partial liver transplant.

3 Feb 2009

Top hospitals have 27 percent lower mortality: Annual HealthGrades study

Medicare patients treated at top-rated hospitals nationwide across the most common Medicare diagnoses and procedures are 27 percent less likely to die, on average, than those admitted to all other hospitals, according to a study released today by HealthGrades, the leading independent healthcare ratings organization.

29 Jan 2009

Repeat cesarean deliveries before 39 weeks raises risk of neonatal illness

Women choosing repeat cesarean deliveries and having them at term but before completing 39 weeks gestation are up to two times more likely to have a baby with serious complications including respiratory distress resulting in mechanical ventilation and NICU admission.

7 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Magnets in toys pose serious health risks

While the danger of magnets for children is increasingly recognized, they don't receive treatment for swallowing them as quickly as needed, and parents don't receive sufficient warning on toys, according to a new study.

10 Dec 2008

Dacogen data presented on trial in seniors with acute myeloid leukemia

Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.

10 Dec 2008

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Sanofi-aventis has announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology.

7 Dec 2008

Novel target for therapeutics against Staphylococcus aureus

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease.

28 Nov 2008

Ortho Biotech submits NDA for Trabectedin in relapsed ovarian cancer

Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).

20 Nov 2008

CAPHOSOL shown to benefit cancer patients undergoing chemotherapy and radiation therapy

New data show that CAPHOSOL, an advanced electrolyte solution, results in low rates of oral mucositis and pain in patients with head and neck (HN) cancer who are undergoing chemotherapy and radiation therapy.

17 Nov 2008

Medicine, math and engineering combine to reveal how sepsis and less severe infections occur

It's a leading cause of death, but no one knows for sure how and why it happens. It's a major source of health care costs, adding days or weeks to the hospital stays and lost work time of millions of people. But no one fully understands how best to fight it.

11 Nov 2008

New report shows high Clostridium difficile infection rates in U.S. hospitals

Consumers Union called on hospitals today to take more aggressive steps to protect patients from Clostridium difficile (C.-diff.) infections in light of a new report showing that they are much more common than previous estimates had indicated. As the rate of hospital acquired C.-diff. infections has jumped in recent years, an increasing number of patients have developed antibiotic-resistant strains of the infection that are more difficult to treat and more deadly.

11 Nov 2008